Wnt9

Wnt9 refers mainly to the paralogous secreted ligands WNT9A and WNT9B, which drive canonical β-catenin-dependent and non-canonical β-catenin-independent Wnt signaling^[1]. Mechanistically, WNT9A supports hematopoietic stem and progenitor cell development, and zebrafish studies show that wnt9a is required for aortic amplification of nascent hematopoietic stem cells^[2][3]. Ligand specificity is experimentally important because EGFR is required for Wnt9a-Fzd9b signaling specificity in hematopoietic stem cells^[4]. Compared with WNT9A, WNT9B has stronger evidence in mouse facial morphogenesis, where ectoderm-derived WNT9b cooperates with mesenchyme-derived RSPO2 to activate canonical WNT/β-catenin signaling^[5]. Disease models further support target selection: loss of Wnt9a aggravates rheumatoid arthritis-like symptoms in chronic TNF-dependent hTNF transgenic mice, but not in acute K/BxN serum-transfer arthritis^[6]. Therefore, Wnt9-focused research should distinguish WNT9A and WNT9B by isoform, receptor context, model organism, and pathway readout before designing agonist or inhibitor experiments^[1][4][5].- WNT9A suits hematopoietic stem cell and inflammatory arthritis models requiring isoform-specific pathway analysis^[2][6]. - WNT9B suits craniofacial morphogenesis studies centered on RSPO2-enhanced β-catenin signaling^[5]. - Experimental modulation should define ligand, receptor, pathway readout, and disease model before interpretation^[1][4].